XBIO REPORT – Page 3 – Biotech Stock News

February 7, 2026

TransCode Therapeutics and Quantum Leap Advance TTX-MC138 Development with IND Amendment Submission for Phase 2a Trial

NASDAQ: $RNAZ A Significant Step Forward in Oncology Treatment TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative (QLHC) have jointly announced a noteworthy progression in their ongoing research and development efforts. The companies have officially submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA). This submission pertains to the…

Clinical Trial

$RNAZ, Biotechnology, clinical trials, Drug Development, Glioblastoma, oncology
February 7, 2026

PTC Therapeutics Announces Date for Fourth Quarter and Full-Year 2025 Financial Results

NASDAQ: $PTCT PTC Therapeutics, a biotechnology company focused on developing innovative treatments for rare diseases, has officially announced the date for the release of its financial performance data for the fourth quarter and the entirety of the 2025 fiscal year. Investors, analysts, and stakeholders can anticipate the official announcement on Thursday, February 19, 2026. This…

Stocks

$PTCT, Biotech Earnings, Financial Results, PTC Therapeutics, Q4 2025, Rare Diseases
February 7, 2026

Insmed to Present Fourth Quarter and Full Year 2025 Financial Results

NASDAQ: $INSM Insmed Incorporated has officially announced the schedule for its upcoming financial results presentation. The company will host a conference call to discuss its financial performance for the fourth quarter and the entirety of the fiscal year 2025. This event is set to take place on Thursday, February 19, 2026. The conference call is…

Stocks

$INSM, biopharmaceutical, Conference Call, Financial Results, Insmed, Q4 2025 Earnings
February 7, 2026

Viking Therapeutics Announces Q4 and Full-Year 2025 Financial Results Date

NASDAQ: $VKTX Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and endocrine diseases, has officially announced the date for its upcoming financial report. Investors and interested parties can anticipate the company’s financial results for the fourth quarter and the full year ended December 31, 2025, which will be released…

Announcements

$VKTX, Biopharma Earnings, Financial Results, Q4 2025, Viking Therapeutics
February 7, 2026

Decoy Therapeutics Highlights Global Access Commitment Following Investor Presentation

NASDAQ: $DCOY Decoy Therapeutics Showcases Commitment to Global Accessibility During Recent Investor Event Decoy Therapeutics, Inc. recently participated in a dedicated segment during a virtual investor conference, focusing a significant portion of its presentation on the implications and execution strategy of its recently announced Global Access Commitment Agreement. The company utilized this platform to elaborate…

Conferences

$DCOY, Biotechnology, Decoy Therapeutics, Global Access, Investor Relations, Pharmaceutical Strategy
February 7, 2026

Pharos AI and 10x Genomics Join Forces to Advance Cancer Research Through Integrated Technology

NASDAQ: $TXG A significant collaboration has been established between Pharos AI, a leader in artificial intelligence solutions for the life sciences, and 10x Genomics, a pioneer in single cell and spatial biology technologies. This partnership is set to revolutionize how researchers approach complex challenges in oncology by integrating advanced computational power with cutting-edge molecular analysis.…

Artificial Intelligence

$TXG, artificial-intelligence, Cancer Research, Genomics, Spatial Biology, Translational Medicine
February 7, 2026

Metavia’s Collaboration with Syntekabio Yields Positive AI Modeling Results for Vanoglipel

NASDAQ: $MTVA Metavia, Inc., a company focused on novel therapeutic development, recently announced encouraging results stemming from its ongoing artificial intelligence (AI) modeling collaboration with Syntekabio. These latest findings solidify key therapeutic targets relevant to their lead compound, Vanoglipel, a promising drug candidate. The collaboration leverages Syntekabio’s advanced AI platforms to expedite and refine the…

Artificial Intelligence

$MTVA, AI Drug Discovery, Metavia, Syntekabio, Therapeutic Targets, Vanoglipel
February 7, 2026

Viatris Announces Q4 and Full-Year 2025 Financial Results Date and Investor Event Schedule

NASDAQ: $VTRS Viatris Inc. has officially announced the schedule for reporting its financial outcomes for the fourth quarter and the entirety of the 2025 fiscal year. This important update for investors and stakeholders is set for release on Thursday, February 26, 2026. Following the release of the comprehensive financial figures, Viatris will host a conference…

Stocks

$VTRS, Corporate Announcement, Financial Results, Investor Event, Q4 2025, Viatris
February 7, 2026

Amgen’s 2025 Financial Performance: A Review of Fourth Quarter and Full-Year Results

NASDAQ: $AMGN Amgen recently announced its financial results for the fourth quarter and the full year ended December 31, 2025. The company’s performance reflects ongoing strategic initiatives and the impact of its evolving portfolio in the biotechnology sector. For the fourth quarter of 2025, Amgen reported total revenue of approximately $8.2 billion. This figure marks…

Stocks

$AMGN, Amgen, Biotechnology, Financial Results, Pharma Earnings, Q4 2025
February 7, 2026

Rigel Strengthens Leadership with Appointment of Michael P. Miller to Board of Directors

NASDAQ: $RIGL Rigel Pharmaceuticals, Inc. recently announced a significant addition to its leadership structure with the appointment of Michael P. Miller to its Board of Directors, effective immediately. Mr. Miller brings a wealth of experience in the biotechnology and pharmaceutical sectors, promising to contribute valuable strategic insights as Rigel continues to advance its pipeline and…

Announcements

$RIGL, Biotechnology, Board Appointment, Corporate Governance, Michael P. Miller, Rigel Pharmaceuticals